Aeolus Pharmaceuticals’ proposed treatment for Lou Gehrig’s disease, or ALS, showed promise in recent tests, the company reported this week.

In three studies, genetic animal models treated with AEOL 10150 showed up to three times the survival rate when compared to untreated controls for amyotrophic lateral sclerosis, Aeolus said.

Those treated showed “marked slowing in the rate of disease progression”; the authors of the studies wrote.

The findings were reported in the August 2005 edition of the Annals of Neurology.

Also this week, Aeolus reported a sharp drop in its financial losses. For details see: